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Background. The diagnosis of tuberculous meningitis (TBM) especially in children is challenging. New tests are urgently needed for
the diagnosis of the disease, especially in resource-limited settings. Methods. We collected cerebrospinal ﬂuid (CSF) samples from
children presenting with symptoms requiring investigation for meningitis at a tertiary hospital in Cape Town, South Africa.
Children were later classiﬁed as TBM or no TBM using published case deﬁnitions. Using a multiplex platform, we investigated
the concentrations of biomarkers comprising a previously established 3-marker biosignature (VEGF, IL-13, and LL-37) and
other potentially useful host biomarkers as diagnostic candidates for TBM. Findings. Out of 47 children, age, 3 months to
13 years, 23 were diagnosed with TBM and six (16%) were HIV-infected. We validated the previously identiﬁed CSF
biosignature (sensitivity of 95.7% (95% CI, 79.0-99.2%) and speciﬁcity of 37.5% (95% CI, 21.2-57.3%)). However, substitution of
IL-13 and LL-37 with IFN-γ and MPO, respectively, resulted in improved accuracy (area under the ROC curve AUC = 0 97,
95% CI, 0.92-1.00, up to 91.3% (21/23) sensitivity and up to 100% (24/24) speciﬁcity). An alternative four-marker biosignature
(sICAM-1, MPO, CXCL8, and IFN-γ) also showed potential, with an AUC of 0.97. Conclusion. We validated a previously
identiﬁed CSF biosignature and showed that reﬁnement of this biosignature by incorporation of other biomarkers diagnosed
TBM with high accuracy. Incorporation of these biomarkers into a point-of-care or bedside diagnostic test platform may result
in the improved management of TBM in children.
1. Introduction
Tuberculosis (TB) remains a global health problem and was
responsible for the deaths of estimated 1.6 million people in
2017 [1]. Although it is diﬃcult to accurately estimate the
burden of childhood TB, one million children were estimated
to have become ill with the disease in 2017 [1].
Tuberculous meningitis (TBM) is the most severe form of
extra pulmonary TB as it aﬀects the central nervous system
(CNS). It mostly occurs during early childhood and has high
morbidity and mortality, mainly due to delayed diagnosis [2].
It is well established that diagnosing pulmonary TB disease in
children is challenging, especially in resource-constrained
settings [3]. It is even more challenging to diagnose extrapul-
monary TB in this patient group, including TBM. As a
consequence, TBM frequently results in a poor outcome
due to nonspeciﬁc symptoms and signs [4]. The limitations
of both the most widely used diagnostic test for TB (smear
microscopy) [5] and the culture gold standard test are
well publicised [3, 5]. These tests have been shown to
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be suboptimal in the diagnosis of TBM [6, 7]. The GeneXpert
MTB/RIF test®, the most important recent advancement in
the ﬁeld of TB diagnostics, is limited by the large CSF
volumes required and low negative predictive value [8].
However, the use of the GeneXpert Ultra resulted in an
improved negative predictive value in a more recent study
on HIV-positive adults [9]. The diagnosis of TBM is mostly
based on a combination of clinical ﬁndings, multiple labora-
tory tests on the CSF, imaging ﬁndings, and the exclusion of
common diﬀerential diagnoses in routine clinical practice
[10]. Diagnosing the disease in most high-burden, but
resource-constrained settings is diﬃcult due to the unavail-
ability of most of these techniques, with children seen at
primary and secondary healthcare facilities often having
multiple missed opportunities; up to six visits before the
eventual diagnosis of TBM are made [11]. New tests are
urgently needed for the diagnosis of TBM.
Host biomarker-based tests may be valuable in the
diagnosis of TBM as they have previously been shown to be
potentially useful in other extrapulmonary forms of TB
[12] and may be easily converted into point-of-care or
bedside tests [13, 14]. In a previous study, we identiﬁed
a 3-marker CSF host protein biosignature comprising
VEGF, IL-13, and cathelicidin LL-37, which showed
potential in the diagnosis of TBM in children [15]. As
there have been multiple recent studies in which new,
potentially useful TB diagnostic biomarkers were identiﬁed
[16, 17], we hypothesized that at least some of these bio-
markers, which were identiﬁed in mostly adult pulmonary
TB studies, will be useful in the diagnosis of TBM in
children. We therefore aimed to evaluate the usefulness
of our previously established 3-marker CSF biosignature
in a new cohort of children with suspected meningitis
and to also evaluate the potential of other host biomarkers
that have shown potential in adult pulmonary TB studies,
as candidate markers for the diagnosis of TBM in chil-
dren. We further hypothesized that the accuracy of the
previously identiﬁed 3-marker CSF signature [15] may be
improved if reﬁned through the incorporation of some of
these new biomarkers.
2. Materials and Methods
Children suspected of having meningitis and requiring CSF
examination for routine diagnostic purposes were recruited
from the Tygerberg Academic Hospital in Cape Town, South
Africa. Study participants were recruited between November
2016 and November 2017. Children were eligible for partici-
pation in the study if they were between the ages 3 months
and 13 years, provided that written informed consent was
obtained from the parents or legal guardians. Assent was
obtained from children older than 7 years if they had a
normal level of consciousness, i.e., a Glasgow Coma Score
(GCS) of 15/15. The study was approved by the Health
Research Ethics Committee of the University of Stellenbosch,
Tygerberg Academic Hospital, and the Western Cape
Provincial Government.
After the collection of CSF and blood samples for routine
diagnostic purposes, an additional 1ml of CSF was collected
into a sterile tube (BD Biosciences). Samples were then taken
to the immunology research laboratory for further process-
ing for research purposes, within an average of 2 hours from
collection. CSF samples were centrifuged in a biosafety level 3
laboratory at 4000 xg for 15 minutes, followed by aliquoting
and storage at -80°C until analysed.
2.1. Diagnostic Work-Up of Study Participants. All patients
underwent a comprehensive clinical evaluation by a specialist
paediatric neurologist. After routine clinical investigations,
computed tomography (CT) of the brain, air encephalogra-
phy, and magnetic resonance (MR) imaging were per-
formed as clinically indicated. Following lumbar puncture,
investigations including appearance and colour determina-
tion, diﬀerential cell counts, protein, glucose, and other
routinely investigated markers (Supplementary Table 1)
were assessed, followed by centrifugation of the CSF, Gram
staining, India ink examination, culture of the centrifuged
sediment on blood agar plates (for pyogenic bacteria),
auramine “O” staining and ﬂuorescence microscopy, culture
using the mycobacterium growth indicator tubes (MGIT)™
method (Becton and Dickinson), and examination for M.tb
DNA using the HAIN Genotype MTBDRplus kit (Hain
Lifescience GmbH, Germany). All data generated from
the study were recorded in a study-speciﬁc RedCap
web-based database.
Patients were classiﬁed as possible, probable, or deﬁnite
TBM according to a uniform research case deﬁnition based
on a scoring system consisting of clinical, CSF, and neuroim-
aging ﬁndings [18]. TBM was classiﬁed as “probable” when
patients scored ≥12 when neuroimaging was available and
≥10 when neuroimaging was unavailable. A diagnosis of
deﬁnite TBM was made if acid-fast bacilli were present in
the CSF, M.tb was isolated from the CSF by cultured, a
nucleic acid ampliﬁcation test of CSF yielded positive results,
or there was histopathological evidence ofM.tb from another
CNS sites.
2.2. Immunoassays. In addition to the three biomarkers that
comprised our previous 3-marker model [15] (IL-13, VEGF,
and cathelicidin LL-37), we evaluated the concentrations of
66 other candidate biomarkers including markers that were
previously investigated in adult TB studies [16, 17, 19, 20]
and other proteins which have not been previously investi-
gated in the TB ﬁeld, including complement factors and
other proteins, as possible diagnostic biomarkers for TBM
by ELISA (cathelicidin LL-37) or the Luminex platform (all
other host biomarkers).
Cathelicidin LL-37 levels in CSF samples were evaluated
using an ELISA kit purchased from Elabscience Biotechnol-
ogy Inc. (catalog #E-EL-H2438). Experiments were done
according to the procedure recommended by the manufac-
turer after which optical densities (OD) were read at
450 nm by an automated microplate reader (iMark™ Micro-
plate Reader, Bio-Rad Laboratories). The mean OD of the
blank wells was subtracted from the OD of the sample
wells and the background-corrected ODs used for statisti-
cal analysis.
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The concentrations of CCL1 (I-309), CCL2 (MCP-1),
CCL3 (MIP-1α), CCL4 (MIP-1β), CD40 ligand (CD40L),
CXCL8 (IL-8), CXCL9 (MIG), CXCL10 (IP-10), granulocyte
colony-stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), interferon gamma
(IFN-γ), interleukin- (IL-) 1β, IL-10, IL-12/23 (p40), IL-
17A, IL-21, IL-4, IL-6, IL-7, matrix metalloproteinase-
(MMP-) 1, MMP-8, transforming growth factor- (TGF-) α,
tumour necrosis factor- (TNF-) α, soluble neural cell adhe-
sion molecule (sNCAM-1/CD56), MMP-7, ferritin, and
MMP-9 were evaluated in patient samples using Luminex
kits purchased from R&D Systems Inc. (Bio-Techne),
Minneapolis, USA. The levels of apolipoprotein- (Apo-) AI,
Apo-CIII, complement C3, complement factor H, BDNF,
cathepsin D, soluble intracellular adhesion molecule-
(sICAM-) 1, myeloperoxidase (MPO), platelet-derived
growth factor- (PDGF-) AA, CCL5 (RANTES), PDGF-
AB/BB, soluble vascular adhesion molecule (sVCAM-1),
plasminogen activator inhibitor-1 (PAI-1) (total), S100
calcium-binding protein B (S100B), amyloid beta 1-40
(Ab40), Ab42, soluble receptor for advanced glycation end
products (sRAGE), Glial cell-derived neurotrophic factor
(GDNF), C-reactive protein (CRP), alpha-2-antitrypsin
(A1AT), pigment epithelium-derived factor (PEDF), serum
amyloid P (SAP), CCL18 (MIP-4/PARC), complement C4
(CC4), CC2, CC4b, CC5, CC5a, CC9, complement factor D
(CFD/adipsin), mannose-binding lectin (MBL), complement
factor 1 (CF1), sP-selectin, von Willebrand factor-cleaving
protease (ADAMTS13), D-DIMER, growth diﬀerentiation
factor- (GDF-) 15, myoglobin, lipocalin 2 (NGAL), and
serum amyloid A (SAA) were evaluated using kits purchased
from Merck Millipore, Billerica, MA, USA. All biomarkers
were evaluated in CSF samples collected from all study
participants following the instructions of the respective
kit manufacturers (R&D Systems and Merck Millipore),
respectively. All experiments were performed on the Bio
Plex platform (Bio Rad Laboratories, Hercules, USA) in
an ISO 15189 accredited laboratory. Data acquisition and
analysis of median ﬂuorescent intensity were done using
the Bio Plex Manager version 6.1 software (Bio Rad Labo-
ratories). The laboratory staﬀ performing the Luminex
experiments were blinded to the clinical classiﬁcation of
the study participants. The values of analytes in the quality
control reagents evaluated with the samples were within
their expected ranges.
2.3. Statistical Analysis. Diﬀerences in the concentrations of
host biomarkers between the TBM and the no TBM groups
were assessed using the Mann–Whitney U test. The receiver
operator characteristic (ROC) curve analysis procedure was
used to assess the diagnostic accuracy of individual host
biomarkers for TBM. Optimal cut-oﬀ values and associated
sensitivities and speciﬁcities were selected based on Youden’s
index [21]. The utility of combinations of biomarkers in the
diagnosis of TBM was ascertained by general discriminant
analysis (GDA), followed by leave-one-out cross-validation.
The data was analysed using Statistica (TIBCO Software
Inc., CA, USA), and GraphPad Prism version 6 (GraphPad
software, CA, USA).
3. Results
A total of 47 children in whom meningitis was strongly
suspected, 30 (63.8%) of whom were males, were included
in the study (Figure 1). The median age of all the children
was 22 months (interquartile range: 10.5 to 57 months),
and six out of 37 with known HIV status (16.2%) were
HIV-infected. Using a composite reference standard based
on a uniform research case deﬁnition of TBM [18], 23 of
the children were diagnosed with deﬁnite or probable
TBM (definite = 2; probable = 21). The 24 children without
TBM included children with bacterial meningitis (n = 2)
and viral meningitis (n = 2) and children with other
diagnoses (Table 1).
3.1. Usefulness of the Previously Identiﬁed 3-Marker CSF
Biosignature in the Diagnosis of TBM. As we were interested
in validating the diagnostic accuracy of the previously estab-
lished 3-marker CSF biosignature (VEGF, IL-13, and catheli-
cidin LL-37), we ﬁrst looked at the utility of individual
analytes comprising this signature, followed by the evalu-
ation of combinations between diﬀerent biomarkers com-
prising the signature.
As observed in our previous study [15], VEGF was the
most useful individual biomarker in this signature as none
of the other two markers showed signiﬁcant diﬀerences
between groups with the Mann–Whitney U test. The median
levels of all the three analytes were higher in children with
TBM (Table 2). As reagent kits from diﬀerent manufacturers
were used in this study, in comparison with what was
employed in the previous study, we performed receiver
operator characteristic (ROC) curve analysis to ascertain
the optimal threshold values for the analytes using these
new reagent kits. Using these new cut-oﬀ values, we observed
that combining all three biomarkers (that is, a patient yield-
ing positive results with all three), or positivity with any
two out of the three analytes, was inferior to the accuracy
obtained with VEGF A alone. However, when considering
values above the threshold for any one of the three markers
taken as a positive result, the accuracy of the 3-biomarker
signature improved, with positive and negative predictive
values of 59.5% (95% CI, 51.5-66.9%) and 90.0% (95% CI,
55.3-98.5%), respectively (Table 2).
3.2. Utility of Alternative Host Biomarkers in the Diagnosis of
TBM.When the concentrations of the other 66 host markers
investigated in our study were compared between children
with and those without TBM using the Mann–Whitney U
test, the levels of multiple host biomarkers were signiﬁcantly
diﬀerent (p ≤ 0 05) between the two groups (Supplementary
Table 2). When the data for individual host markers were
assessed by ROC curve analysis, the area under the ROC
(AUC) was above 0.70 for 45 of the 66 proteins. Of note,
the AUCs for 28 of these proteins including IFN-γ, MIP-4,
CXCL9, CCL1, RANTES, IL-6, TNF-α, MPO, MMP-9,
MMP-8, CC2, IL-10, PAI-1, CXCL8, IL-1b, A1AT,
CXCL10, G-CSF, CC4, CC4b, GM-CSF, PDGF AB/BB,
Apo-AI, MBL, ferritin, CC5a, SAP, and CC5 were ≥0.80
(Figure 2, Supplementary Table 2).
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As all the six knownHIV-infected children were in the no
TBM group, we excluded these children and reanalysed the
data for individual host biomarkers, to assess the possible
inﬂuence of HIV infection on the accuracy of the biomarkers.
After excluding the HIV-infected children, the median levels
of PEDF, IL-12/23p40, MMP-1, CD40L, and GDF-15 were
no longer signiﬁcantly diﬀerent between the children with
TBM vs. no TBM. CD40L and GDF-15 showed trends for
Table 1: Clinical and demographic characteristics of children included in the study.
All TBM No TBM#
Number of participants 47 23 24
Median age, months (IQR) 22.0 (10.5-57.0) 18.0 (11.0-40.0) 30.0 (9.0-96.0)
Males, n (%) 30 (63.8) 13 (56.5) 17 (70.8)
HIV-positive, n/not tested 6/37 0/22 6/15
#The no TBM group included children with bacterial meningitis (n = 2), viral meningitis (n = 2), asphyxia (n = 1), autoimmune encephalitis (n = 1), febrile
seizure (n = 3), Guillain Barre (n = 1), HIV encephalopathy (n = 1), focal seizures (n = 1), leukemia (n = 1), miliary TB (with lymyphocytic interstitial
pneumonitis) (n = 1), developmental delay (n = 1), breakthrough seizure (n = 1), gastroenteritis (caused by shock) (n = 1), idiopathic intracranial
hypertension (IIH) (n = 1), viral gastroenteritis (adeno and rota) and encephalopathy (n = 1), stroke (n = 1), mitochondrial diagnosis (n = 1), viral
pneumonia (this included also SAM and nosocomial sepsis) (n = 1), febrile seizure and acute gastroenteritis (n = 1), and others (n = 1). IQR: interquartile range.
Send 1mL of CSF to
research laboratory
69 host markers evaluated
(n = 47) 
Child aged 3 months to 13
years strongly suspected
of having meningitis
Informed consent
Assent
Completion of CRF 
Definite or probable TBM
(n = 23)
No TBM
(n = 24)
(i)
(i)
(i)
(i)
(ii)
(iii)
(ii)
(iii)
Clinical assessment
Diagnostic imaging
procedures
Collection of samples
for routine diagnostic
investigations
(n = 47)
Classification of study
participants using a
uniform research case
definition
Figure 1: STARD diagram showing the study design and classiﬁcation of study participants. CRF: case report form; TBM: tuberculous
meningitis; no TBM: individuals presenting with symptoms and investigated for TB but TBM ruled out. The no TBM group included
bacterial meningitis (n = 2), viral meningitis (n = 2), and children with other diagnoses (Table 1).
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signiﬁcant diﬀerences (0.05< p-value ≤ 0.09), whereas the
observations for all other host markers were unchanged (data
not shown).
3.3. Utility of Combinations between Other Host Biomarkers
in the Diagnosis of TBM.When the data obtained for all host
markers (including VEGF A, IL-13, and LL-37) were ﬁtted
into general discriminant analysis (GDA) models irrespective
of HIV status, optimal prediction of TBM was shown to be
achieved with a combination of four markers. The most accu-
rate four-marker biosignature is comprised of sICAM-1,
MPO, CXCL8, and IFN-γ diagnosed TBM with an AUC of
0.97 (95% CI, 0.92-1.00), corresponding to a sensitivity of
87.0% (20/23) (95% CI, 66.4-97.2%) and speciﬁcity of
95.8% (23/24) (95% CI, 78.9-99.9%). After leave-one-out
cross validation, there was no change in the sensitivity
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Figure 2: Representative plots showing the concentrations of biomarkers detected in CSF samples from children with and without TBM and
ROC curves showing the accuracies of these biomarkers in the diagnosis of TBM. Error bars in the scatter-dot plots indicate the median and
interquartile ranges. Representative plots for six analytes with AUC ≥ 0 80 are shown. The accuracies of all host biomarkers evaluated in the
study are shown in Supplementary Table 2.
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(87.0%) and speciﬁcity (95.8%) of the four-marker biosigna-
ture. The positive and negative predictive values of the
biosignature were 95.2% (95% CI, 74.5-99.3%) and 88.5%
(95% CI, 72.7-95.7%), respectively. Further optimization of
the four-marker biosignature resulted in both sensitivity
and speciﬁcity (96%) (Figure 3).
Given that VEGF has consistently shown promise as a
biomarker for TBM [15, 22–24] and that we identiﬁed other
candidate biomarkers with strong potential in the present
study, we wondered whether the previous 3-marker VEGF-
based biosignature could be further optimized using other
analytes. A GDA model in which IL-13 and cathelicidin
LL-37 were replaced with IFN-γ and MPO, respectively,
resulted in an improved AUC of 0.97 (95% CI, 0.92-1.00),
corresponding to a sensitivity of 82.6% (19/23) (95% CI,
61.2-95.1%) and speciﬁcity of 95.8% (23/24) (95% CI, 78.9-
99.9%). After leave-one-out cross validation, the sensitivity
and speciﬁcity of the biosignature were 78.3% (18/23) (95%
CI, 56.3-92.5%) and 91.7% (22/24) (95% CI, 73.0-99.0%),
respectively. The positive and negative predictive values of
the reﬁned VEGF-based biosignature after leave-one-out
cross validation were 90.0% (95% CI, 70.1-97.2%) and
81.5% (95% CI, 66.8-90.6%), respectively. Further optimiza-
tion of the biosignature through the selection of better cut-
oﬀ values resulted in improved sensitivity and speciﬁcity of
92% and 100%, respectively (Figure 4).
4. Discussion
We assessed the utility of a previously identiﬁed 3-marker
CSF biosignature (IL-13, VEGF, and cathelicidin LL-37)
[15] as well as host biomarkers that have shown potential
as pulmonary TB diagnostic candidates in recent adult
studies, as tools for the diagnosis of TBM in children with
suspected meningitis. Although we validated the diagnostic
accuracy of the previously identiﬁed 3-marker biosignature,
other major ﬁndings from our study included the identiﬁ-
cation of a novel four-marker CSF biosignature compris-
ing sICAM-1, MPO, CXCL8, and IFN-γ and a modiﬁed
3-marker signature (VEGF, IFN-γ, and MPO) which diag-
nosed TBM with promising accuracy. We also identiﬁed
multiple host biomarkers that are detectable in CSF and
which showed strong potential as diagnostic candidates for
TBM in children.
It is well known that the diagnosis of TB disease in
children remains a major challenge worldwide. This is
mainly due to several well-publicised limitations in the
currently available diagnostic tools [3, 5]. It is even more
challenging to diagnose extrapulmonary TB including TBM
in this patient group, with unstandardized and cumbersome
approaches without reliable diagnostic criteria currently
being used in routine clinical practice [25, 26]. In order to
improve standardization of clinical diagnosis of TBM for
research purposes, a uniform research case deﬁnition for
both adults and children was proposed, categorizing patients
as deﬁnite, probable, or possible TBM according to a
composite score based on clinical, CSF, and neuroimaging
ﬁndings [18]. None of the tests that are used in the diagnosis
of TBM in children performs with high accuracy individually
[6, 7, 27, 28]. The disease consequently results in high mor-
bidity and mortality, due mainly to diagnostic delay [2, 29].
Host inﬂammatory biomarker-based biosignatures have
been shown to have potential in the diagnosis of TB disease
in both adults and children in previous studies [16, 20, 30].
Furthermore, these immunological biomarker-based tests
have the potential to be readily converted into user-friendly,
point-of-care diagnostic tests [13, 14] with the development
of such tools for the management of TBM especially in
children promising to be a major breakthrough in the future.
In the present study, we validated the diagnostic accuracy of a
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Figure 3: Accuracy of the 4-marker CSF biosignature (sICAM-1, MPO, CXCL8, and IFN-γ) in the diagnosis of TBM. Scatter plot showing the
ability of the 4-marker signature to classify children as TBM or no TBM (a). ROC curve showing the accuracy of the 4-marker biosignature
(b). Red squares: children with TBM. Blue circles: children with no TBM.
7Mediators of Inﬂammation
previously identiﬁed CSF inﬂammatory biomarker-based
biosignature [15]. Although a diagnostic test with positive
and negative predictive values of 59.5% and 90.0%, respec-
tively, will be imperfect, such a test may indeed contribute
signiﬁcantly to the management of children with suspected
TBM if it is a rapid, point-of-care or bedside test, considering
that it currently takes up to six hospital visits before TBM is
diagnosed in children with the current diagnostic approaches
in a country such as South Africa, which is relatively well
resourced, compared to other lower- and middle-income
countries [11]. Our data indicates that replacement of two
of the proteins in this previously identiﬁed signature (IL-13
and cathelicidin LL-37) with new biomarkers (MPO and
IFN-γ, respectively) has the potential to yield a test with
both sensitivity and speciﬁcity (>95%). Furthermore, host
markers comprising the alternative four-marker biosignature
(sICAM-1, MPO, CXCL8, and IFN-γ) and other analytes
that showed potential individually may be backup host
markers that might be employed during the development of
such a test. Our ﬁndings may therefore pave the way for the
development of a prototype CSF biomarker-based test for
the diagnosis of TBM in children.
During the development of such a test, the biosignature
could be optimized further for use as a rule-in or rule-out test
and the newly developed tests used as a screening test for
TBM. If the test is based on a point-of-care diagnostic
platform, such as the lateral ﬂow technology, successful
implementation of the test at the point-of-care or bedside
would lead to a signiﬁcant reduction in the costs and delays
that are currently incurred in the diagnosis of TBM in
children [11], with a consequent reduction in morbidity
and mortality. Although a CSF-based point-of-care or
bedside test will be useful in the management of TBM in
children, the expertise required for lumbar punctures,
opposed to that needed for the collection of other samples
such as blood, saliva, or urine, may be a challenge in
resource-limited settings, making the implementation of
such a diagnostic tool diﬃcult. That notwithstanding, such
a test will also contribute to the management of the disease
in children where sample collection is possible.
The fact that host inﬂammatory biomarkers detectable
in CSF show potential in the diagnosis of TBM is not
surprising, given that previous studies identiﬁed VEGF
and other candidate biomarkers [15, 22–24] as potential
tools for the diagnosis of the disease. Such candidate bio-
markers that are detectable in biological ﬂuids including
blood [16, 17, 31–33], saliva [19, 20, 34], urine [35], and other
specimens [12, 14, 36, 37] have been identiﬁed as TB
diagnostic candidates in several previous studies. It is well
established that individual host biomarkers might not suﬃce
as diagnostic tools for TB disease [16, 31, 33] owing to the
fact that these inﬂammatory biomarkers will be raised in
other diseases, including cancers. However, these speciﬁcity
concerns may be addressed through the use of a panel of
biomarkers as done in the present study.
The main limitation of the current study was the
relatively small sample size, especially the few children with
conﬁrmed TBM and alternative diagnoses including children
with other forms of meningitis. However, as this was a TBM-
suspect study, the design of the study was relatively strong
and the number of participants enrolled into the study is
consistent with the patient numbers described in multiple
previous studies. Validation of the previously established
3-marker CSF signature in the current study indicates that
the novel biosignatures identiﬁed in the study have strong
potential. Further studies should include larger numbers of
study participants with suspected meningitis, including those
who are HIV-infected, and individuals with conﬁrmed
alternative meningitides. HIV-infected children included in
such studies should be appropriately staged with CD4 counts
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Figure 4: Accuracy of a new VEGF-based 3-marker CSF biosignature in the diagnosis of TBM. Scatter plot showing the ability of the
3-marker signature to classify children as TBM or no TBM (a). ROC curve showing the accuracy of the 3-marker biosignature
(VEGF, IFN-γ, and MPO) (b). Red squares: children with TBM. Blue circles: children with no TBM.
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and viral loads, to assess the possible inﬂuence of severe HIV
infection on the accuracy of the diagnostic biosignatures. For
the biosignatures described in the current study to be useful
in the management of children with suspected TBM, the
biosignatures would require incorporation into a point-of-
care or bedside diagnostic test platform, for example, based
on the lateral ﬂow technology. Such prototype blood-based
TB tests have been developed and successfully investigated
in multiple African countries [13, 14], with multibiomarker
ﬁnger prick-based formats currently under the develop-
ment for the diagnosis of adult pulmonary TB disease
(http://www.screen-tb.eu). Incorporation of host inﬂamma-
tory biomarkers into such a platform may be relatively easier
and faster as lessons learned during the development of adult
pulmonary TB tests will be beneﬁcial.
In conclusion, we validated a previously established
3-marker CSF biosignature as a tool for the adjunctive
diagnosis of TBM in children and furthermore showed
that modiﬁcation of this signature through the substitution
of two of the proteins with new protein biomarkers results
in a strong biosignature for the diagnosis of the disease.
These biosignatures will only be beneﬁcial for people who
would beneﬁt from the urgently required new tools (children
with suspected TBM, parents) if these signatures are further
validated in other geographical areas and are developed in
point-of-care or bedside diagnostic tests. Our study therefore
paves the way for the development of such a prototype test.
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